Mylan has a vast manufacturing platform in India which comprises nine 8 pharmaceutical ingredient (API), 6 oral solid dose (OSD) and 5 injectables manufacturing units that serve a number of markets around the world and produce medicines in a wide range of therapeutic areas.
Seventeen of Mylan’s facilities in India, including nine of its API facilities, are approved by the U.S. Food and Drug Administration (FDA). Many of the sites also are approved and regularly inspected by other regulatory authorities, including Australia's Therapeutic Goods Administration, the U.K.’s Medicines and Healthcare Products Regulatory Agency and the World Health Organization.
Mylan’s globally integrated R&D platform is expanding our product portfolio to satisfy unmet medical needs. We have < 3000 scientific affairs workforce who work collaboratively across multiple R&D centers around the world. About half of our scientific affairs workforce is based in India.